The pharmaceutical industry is bracing for a seismic shift. As the patent protections for Merck & Co.’s blockbuster cancer drug, Keytruda (pembrolizumab)—the world’s bestselling medication—begin to sunset starting in 2028, the race to bring biosimilar alternatives to market has officially begun. With global revenues for Keytruda hitting an staggering $31.7 billion in 2025 alone, the stakes for manufacturers, healthcare providers, and patients could not be higher.
While the FDA recently reached a significant milestone by accepting the first application for a Keytruda biosimilar—Formycon and Zydus Lifesciences’ candidate, FYB206—the path to market remains fraught with complexity. Industry experts warn that even with regulatory approval, these lower-cost alternatives may struggle to gain traction in a market landscape dominated by entrenched, anti-competitive supply chain dynamics.
Main Facts: The Race to Replace a Titan
Keytruda has become the cornerstone of modern oncology, treating over 30 distinct indications. Its dominance, however, has made it a primary target for biosimilar developers. The FDA’s October acceptance of the FYB206 application serves as a bellwether for the industry. If approved, potentially as early as the third quarter of 2027, FYB206 could become the first real challenge to Merck’s oncology crown.
Currently, there are approximately a dozen other candidates in development. These companies are banking on the FDA’s willingness to streamline development pathways. In a notable victory for efficiency, the FDA agreed that FYB206 could move forward without the traditional, resource-heavy comparative Phase 3 efficacy trials. By relying on rigorous analytical and clinical data to prove similarity rather than replicating clinical trials for every cancer type, developers hope to lower the barrier to entry for complex biologics.
However, the "biosimilar void" remains a stark reality. While the FDA has approved over 85 biosimilars to date, their collective market share remains stubbornly below 20%. The promise of lower costs—biosimilars typically cost 50% less than their reference products—has yet to translate into widespread adoption or meaningful relief for the average consumer.
A Chronology of the Biosimilar Movement
The journey toward a post-patent Keytruda landscape has been characterized by slow, deliberate policy shifts and aggressive industrial maneuvering:
- 2018: The FDA releases its "Biosimilars Action Plan," a strategic document aimed at fostering competition by simplifying the approval process and clarifying regulatory requirements.
- 2025: Merck & Co. reports $31.7 billion in annual revenue for Keytruda, underscoring its status as the most lucrative drug in history.
- October 2026: The FDA accepts the application for FYB206, the first publicly announced Keytruda biosimilar. This marks the beginning of the formal regulatory review process for the drug.
- 2027 (Projected): The earliest potential approval window for FYB206.
- 2028: The critical "patent cliff" begins, where key intellectual property protections for Keytruda start to expire, officially opening the door for widespread competition.
- 2034: The broader deadline by which an estimated 118 biologic medicines, representing $232 billion in annual market value, will face potential competition from biosimilars.
Supporting Data: The Cost of Complexity
The economic argument for biosimilars is overwhelming on paper. According to the Biosimilars Forum, the U.S. healthcare system has already saved an estimated $56 billion through the introduction of biosimilar competition. Projections suggest that an additional $181 billion could be saved over the next five years if market penetration increases.
Despite these figures, the disparity between biologic drug spending and patient usage remains a point of contention. Biologics account for only 5% of all prescriptions in the United States, yet they represent a massive 51% of total drug spending. This imbalance is the primary driver for federal efforts to accelerate biosimilar development.
However, the "rebate trap" creates a counter-incentive. Because Pharmacy Benefit Managers (PBMs) often negotiate significant rebates from brand-name manufacturers in exchange for preferred placement on insurance formularies, there is a systemic financial incentive to favor high-cost, high-rebate drugs over lower-cost, no-rebate biosimilars. This creates a "rigged" environment where clinical efficacy and price savings take a backseat to the financial interests of intermediaries.
Official Perspectives and Regulatory Hurdles
The approval of FYB206 represents a collaborative effort between the FDA and private industry to prove that biosimilars can be brought to market faster without sacrificing safety. Dr. Stefan Glombitza, CEO of Formycon, noted that the agreed-upon development pathway allows for substantial reductions in investment while maintaining "rigorous scientific standards."
From a regulatory standpoint, the FDA is attempting to set a precedent. If the approval of FYB206 proceeds without complications, it could provide a roadmap for future manufacturers to bypass expensive, redundant trials. Yet, the question of indications remains. Keytruda’s vast label—covering dozens of cancers—presents a legal minefield.
Michael Abrams, managing partner at Numerof & Associates, highlights the tension between regulatory approval and market reality: "The FDA and the sponsor had to agree on tests and measures to assess whether this biosimilar is as safe and as effective as the reference product. If it goes as they anticipated, this will get approved and the precedent will stand. However, some indications could still be excluded if Keytruda has unexpired orphan-drug exclusivity."
The industry remains deeply skeptical of legislative attempts to fix the problem. As Abrams observes, current reforms have largely "nibbled around the edges." Without structural changes to the PBM model and the opaque rebate system, the regulatory tailwinds provided by the FDA may not be enough to overcome the entrenched commercial barriers.
Implications: A System at a Crossroads
The fate of Keytruda biosimilars is more than just a battle over a single drug; it is a test case for the future of the U.S. pharmaceutical market. If the first wave of Keytruda biosimilars fails to achieve significant market share, the chilling effect on investment will be immediate. Why would venture capital and pharmaceutical firms pour billions into developing biosimilars if the market is structurally prohibited from adopting them?
The implications for the U.S. healthcare system are profound. If the "status quo" persists, the projected $181 billion in savings will likely remain "left on the table." This failure to capture savings directly impacts patient out-of-pocket costs and the long-term sustainability of Medicare and private insurance premiums.
For the system to evolve, experts argue that there must be a greater focus on the "tangle of deals" between drug companies, PBMs, insurers, and hospitals. These arrangements are often so well-hidden that even regulators struggle to evaluate their anti-competitive nature. Unless these relationships are unwound or forced into transparency, the promise of the "patent cliff" will be nothing more than a theoretical event.
As the industry moves toward 2028, all eyes will be on FYB206. It is not merely a product launch; it is a referendum on the American pharmaceutical pricing model. For the developers, the goal is simple: prove the science, pass the regulatory hurdle, and hope the market is actually free enough to allow a cheaper, equally effective cancer treatment to reach the patients who need it most. Whether the system will allow that to happen, however, remains the great unanswered question of the decade.
About the Author
